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ntroduction
nvasive  Aspergillus  infections  are  a  serious  issue
orldwide,  including  the  Middle  East  region.  They
re associated  with  high  morbidity  and  mortality
nd are  a  burden  on  healthcare  services.  Invasive
spergillosis (IA)  is  generally  an  opportunistic  infec-
ion that  affects  immune-deﬁcient  patients  and  is
elated to  defects  in  phagocytosis  and  T  cells  in
umber and/or  function  [1].
Invasive pulmonary  aspergillosis  and  dissemi-
competent  and/or  less  severely  immunocompro-
mised hosts.  These  include  chronic  necrotising
pulmonary aspergillosis  (CNPA),  aspergilloma,  aller-
gic bronchopulmonary  aspergillosis  (ABPA)  and
Aspergillus  sinusitis,  which  can  be  allergic,  inva-
sive or  granulomatous.  Single-organ  involvement
is well  documented  in  the  literature  and  includes
eye, bone,  joint,  heart  and  skin  and  soft  tissue
aspergillosis [2].
Patients  with  acute  leukaemia,  solid  organ  trans-
plant recipients  and  haematopoietic  stem  cellated Aspergillus  infections  are  the  two  most
ommon forms  of  disease  in  severely  immuno-
ompromised individuals.  Several  other  forms  of
spergillosis  have  been  described  in  immune
t
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that  these  guidelines  should  be  followed  as  closely  as
ransplant  recipients  account  for  29%,  9%  and  32%  of
ll Aspergillus  infections,  respectively  [3].  Overall,
early 30%  of  all  invasive  fungal  infections  in  neu-
ropenic  patients  undergoing  cancer  chemotherapy
H.M.  Al-Abdely  et  al.
Table  1  Grading  system.
Grade  Deﬁnition
A  Strongly  recommended  based  on  evidence
from  ≥1  properly  randomised,  controlled
trial
B  Recommended,  based  on  evidence  from  ≥1
well-designed  clinical  trial;  from  cohort  or
case-controlled  analytic  studies,  from
multiple  case  series
C  Recommendation  based  on  limited  data
from  few  retrospective  case  series,  case
reports,  preclinical  studies  and  expert
opinion
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are  caused  by  Aspergillus  spp  [4].  Attributable
mortality rates  in  patients  with  IA  typically  range
from  30%  to  60%  [5—7]. The  economic  burden  of
aspergillosis-related  hospitalisations  is  also  con-
siderable,  even  after  the  introduction  of  new
antifungal treatments.  In  a  study  by  Kim  et  al.,  costs
and outcomes  of  IA-related  hospitalisation  relative
to antifungal  therapy  were  investigated  [8]. The
median  length  of  stay  was  23  days  and  the  median
hospital costs  were  $52,803,  with  intravenous  anti-
fungals accounting  for  7.2%  (range:  0.78—15.9%)  of
the cost  of  aspergillosis-related  hospitalisation.
Signiﬁcant  data  have  been  published  over  the
past two  decades  on  various  aspects  of  IA  that
include epidemiology,  diagnosis  and  therapy  in  sus-
ceptible individuals.  The  ﬁeld  of  antifungal  agents
for aspergillosis  has  expanded  markedly  in  recent
years amid  the  development  of  several  classes  of
mould-active  agents.  These  include  several  new-
generation  triazoles,  echinocandins  and  less  toxic
formulations  of  amphotericin  B.
Taking  into  account  the  lack  of  published
regional studies,  the  limited  diagnostic  resources
and other  speciﬁc  challenges  facing  the  Middle
East countries,  an  expert  panel  from  the  region
reached consensus  on  treatment  guidelines  for
invasive  Aspergillus  infections  in  the  Middle  East.
These are  the  ﬁrst  treatment  guidelines  for  invasive
Aspergillus  infections  that  have  been  produced  for
the region.  Such  regional  guidelines  for  the  treat-
ment of  IA  are  needed  to  account  for  the  regional
epidemiology of  aspergillosis,  available  laboratory
resources and  treatment  options.
Methods
Expert panel
A  panel  of  experts  met  on  June  15,  2012  in  Dubai  to
reach consensus  and  develop  clear  clinical  practice
guidelines  to  aid  diagnosis  and  treatment  of  inva-
sive Aspergillus  infections  in  the  Middle  East.  The
panel included  specialists  in  infectious  diseases  and
intensivists  with  expertise  in  the  management  of
invasive Aspergillus  infections.
Evidence evaluation
Recommendations  from  the  most  recent  interna-
tional guidelines  for  invasive  Aspergillus  infections
were  reviewed  prior  to  the  expert  panel  meet-
ing. The  panel  critically  analysed  recommendations
from these  guidelines  and  reviewed  the  available
published literature  on  the  diagnosis  and  treatment
T
m
a
af  invasive  Aspergillus  infections.  These  guidelines
ncluded  the  Infectious  Disease  Society  of  America
IDSA) guidelines  on  aspergillosis  2008  [9], the  Euro-
ean Council  on  Infections  in  Leukaemia  (ECIL4)
011 update  [10],  and  the  Australian  guidelines
008 [11].
The validity,  clinical  relevance  and  applicability
f the  evidence  for  invasive  Aspergillus  infections
n the  Middle  East  were  discussed.  After  considering
he evidence,  the  panel  achieved  consensus  on  a
umber of  recommendations  that  are  supported  by
est scientiﬁc  evidence.
evels of recommendation
he  panel  reviewed  several  grading  systems  for  rec-
mmendations  and  agreed  on  a  three-tier  grading
ystem:  Grade  A  supports  a strong  recommendation
ased on  evidence  from  at  least  one  randomised
ontrolled clinical  trial  to  Grade  C  for  which  there
re limited  data  to  support  a recommendation
Table  1).
uideline development
he  discussions  and  consensus  statements  were
ecorded  at  the  meeting  and  written  up  as  a  full
anuscript  draft  by  a professional  medical  writer.
he panel  reviewed,  edited,  and  provided  com-
ents on  the  outline  and  manuscript  drafts  until
 ﬁnal  version  was  reached,  which  was  approved  by
ll members.
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pidemiology of invasive Aspergillus
nfections in the Middle East region
ncidence
spergillus  spp.  are  the  most  commonly  isolated
nvasive moulds  [12].  In  the  Middle  East  region,
nvasive Aspergillus  infections  are  well  documented
nd are  probably  on  the  rise  [13,14],  in  part  due
o evolving  medical  practice  with  an  increase  in
he number  of  immunocompromised  patients  due
o cancer  treatment,  organ  transplantation  and
hronic  immunosuppressive  therapy.  However,  it  is
ifﬁcult to  accurately  assess  mortality  related  to
nvasive Aspergillus  infections  in  the  Middle  East
egion due  to  the  nature  of  the  studies  published
primarily case  studies).  The  lack  of  epidemiologi-
al data  for  Aspergillus  infections  in  the  region  is
lso related  to  the  diagnostic  limitations  due  to  the
imited capability  of  many  laboratories  to  recover
nd identify  these  organisms  from  studied  speci-
ens.
ortality
nvasive  Aspergillus  infections  are  an  important
ause of  morbidity  and  mortality  of  hospitalised
atients. Mortality  from  invasive  Aspergillus  infec-
ions is variable  and  depends  on  the  patient’s
nderlying condition,  site  of  infection  and  timing
nd  selection  of  therapy.  Mortality  can  be  as  high
s 90%  in  stem  cell  recipients  with  disseminated
nd central  nervous  system  (CNS)  disease  [15]. Data
rom prospective  trials  indicate  that  overall  early
ortality  (12  weeks  on  antifungal  therapy)  of  all
isease  entities  ranges  from  30%  to  40%  [16,17].
pecies distribution
ontrary  to  other  parts  of  the  world,  Aspergillus
avus, not  Aspergillus  fumigatus, is the  most  com-
only reported  species  causing  invasive  Aspergillus
nfections in  the  Middle  East  region  [18—20].
spergillus  terreus  may  be  more  common  than  A.
umigatus. In  Asia,  Africa  and  the  Middle  East,
inus aspergillosis  and  Aspergillus  endophthalmi-
is are  well  described  [18]. Alongside  classical  risk
actors for  invasive  Aspergillus, e.g.  prolonged  neu-
ropenia,  organ  transplantation,  graft-versus-host
isease (GVHD)  and  immunosuppression,  other  risk
actors have  been  documented  such  as  chronic
bstructive pulmonary  disease,  liver  failure  and
uberculosis  [18].  Similar  to  data  reported  else-
here,  pulmonary  and  disseminated  disease  are  the
wo most  commonly  encountered  forms  of  IA  in
h
t
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atients  with  haematological  malignancies,  recip-
ents of  allogeneic  stem  cell  transplant  and  solid
rgan transplantation.
iagnosis of invasive Aspergillus
nfections
apid  diagnosis  of  invasive  Aspergillus  infections,
deally to  species  level,  is  very  important  for
avourable clinical  outcome  as  other  moulds  and
esistant  Aspergillus  spp.  can  lead  to  failure  of
ntifungal  therapy.  Diagnosis  of  Aspergillus  infec-
ions are  based  on  a combination  of  clinical  risks,
ymptoms  and  signs,  culture,  histopathology  and
etection  of  the  fungal  components  such  as  the
ell wall  antigen  galactomannan.  The  expert  panel
greed that  the  most  recent  deﬁnitions  of  invasive
ungal  disease  from  the  European  Organisation  for
esearch and  Treatment  of  Cancer/Invasive  Fun-
al Infections  Cooperative  Group  and  the  National
nstitute  of  Allergy  and  Infectious  Diseases  Mycoses
tudy Group  [21]  should  be  used  as  the  reference
tandard in  the  Middle  East  region.  However,  for
ndividual  patient  management,  therapy  can  be  ini-
iated based  on  clinical  judgement  of  the  treating
hysician without  fulﬁlling  disease  deﬁnition.
The criterion  for  proven  invasive  Aspergillus
nfection is  the  demonstration  of  fungal  elements
n disease  tissue  of  most  conditions.  This  could  be
hrough:
 A  sterile  specimen  obtained  by  needle  aspira-
tion of  biopsy  for  microscopic  analysis  that  would
demonstrate  presence  of  hyphae  accompanied  by
evidence of associated  tissue  damage.
 The  recovery  of  a  mould  by  culture  of a  specimen
obtained by  a sterile  procedure  from  a normally
sterile and  clinically  or  radiologically  abnormal
site consistent  with  an  infectious  disease  process,
excluding  bronchoalveolar  lavage  ﬂuid,  a  cranial
sinus cavity  specimen  and  urine.
For an infection  to  be  deemed  probable,  a host
actor, clinical  feature  and  mycological  evidence
ould be  required.  A  possible  infection  requires  a
ost factor  and  a  clinical  feature  without  myco-
ogical evidence  (Table  2). The  criteria  should  be
pplied wherever  possible,  utilising  expert  advice
nd resources  where  appropriate.
The expert  panel  acknowledged  that  not  all
athology laboratories  in  the  Middle  East  region
ave access  to  the  relevant  equipment  and  diagnos-
ic tests.  Therefore,  a local  reference  laboratory
hould be  utilised  if resources  are  not  available
n a local  hospital.  Serological  tests,  Aspergillus
24  H.M.  Al-Abdely  et  al.
Table  2  Criteria  for  probable  and  possible  invasive  Aspergillus  infections.
Host  factors  Clinical  criteria  Mycological  criteriaa
Recent  history  of  neutropenia
(<0.5  ×  109 neutrophils/L  [<500
neutrophils/mm3]  for  >10  days)
temporally  related  to  the  onset
of  fungal  disease
Receipt  of  an  allogeneic  stem
cell  transplant
Lower  respiratory  tract  fungal
disease
The  presence  of  1  of  the  following
3  signs  on  CT:
•  Dense,  well-circumscribed
lesion(s)  with  or  without  a  halo  sign
•  Air  crescent  sign
•  Cavity
Direct test
Mould  in  sputum,  bronchoalveolar
lavage  ﬂuid,  bronchial  brush  or
sinus  aspirate  samples,  indicated
by  1  of  the  following:
•  Presence  of  fungal  elements  by
cytology,  direct  microscopy  or
culture  indicating  a  mould
•  Recovery  of  a  mould  by  culture
Prolonged  use  of  corticosteroids
(excluding  among  patients  with
ABPA)  at  a  mean  minimum  dose
of  0.3  mg/kg/day  or  prednisone
equivalent  for  >3  weeks
Tracheobronchitis
Tracheobronchial  ulceration,
nodule,  pseudomembrane,  plaque,
or  eschar  seen  on  bronchoscopic
analysis.
Indirect  tests  (standardised  and
validated)
•  Detection  of  galactomannan
antigen  in  plasma,  serum,
bronchoalveolar  lavage  ﬂuid  or
cerebrospinal  ﬂuid  (CSF)
•  -D-glucan  detected  in  serum
Treatment  with  other  recognised  T
cell  immunosuppressants,  such
as  cyclosporine,  TNF- blockers,
speciﬁc  monoclonal  antibodies
(such  as  alemtuzumab),  or
nucleoside  analogues  during  the
past  90  days
Sinonasal  infection
Imaging  showing  sinusitis  plus  at
least  1  of  the  following  3  signs:
•  Acute  localised  pain  (including
pain  radiating  to  the  eye)
•  Nasal  ulcer  with  black  eschar
•  Extension  from  the  paranasal
sinus  across  bony  barriers,
including  into  the  orbit
Inherited  severe  immunodeﬁciency
(such  as  chronic  granulomatous
disease  or  severe  combined
immunodeﬁciency)
CNS infection
1  of  the  following  2  signs:
• Focal  lesions  on  imaging
•  Meningeal  enhancement  on  MRI
or  CT
Adapted from Ben de Pauw et al. [21] Clin Infect Dis. 2008;46(12);1813—21.
ABPA, allergic bronchopulmonary aspergillosis; CNS, central nervous system.
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galactomannan  and  -D-glucan,  and  Aspergillus
DNA detection  by  polymerase  chain  reaction  (PCR)
or microarray  are  useful  tests  in  the  early  diagnosis
of IA.  The  panel  recommends  that  the  serological
tests of  Aspergillus  galactomannan  and  -D-glucan
be available  in  typical  tertiary  care  centres  with  a
high number  of  patients  at  risk  for  IA.  National  and
regional  collaboration  for  such  diagnostic  tests  is
highly recommended.
Aspergillus  galactomannan  has  good  sensitiv-
ity and  very  good  speciﬁcity  for  the  diagnosis
of IA  in  patients  with  haematological  cancer  and
haematopoietic  stem  cell  transplant  recipients.
Sensitivity is  in  the  range  of  65—90%  and  speciﬁcity
of about  95%  with  a  cut-off  level  of  0.5  in  serum
[22].  Progressive  increase  in  serum  Aspergillus
antigen levels  over  time  signiﬁes  failure  of  treat-
ment [23].  In  addition,  a  few  studies  demonstrated
that Aspergillus  galactomannan  from  respiratory
secretions obtained  by  bronchoalveolar  lavage  has
d
c
C
eions.
etter  sensitivity  than  Aspergillus  galactomannan
rom serum  in  the  diagnosis  of  invasive  pulmonary
spergillosis [24]. The  expert  panel  recommends
hat this  diagnostic  test  be  done  whenever  feasible.
owever,  antifugal  therapy  should  not  necessarily
e discontinued  once  galactomannan  antigenaemia
eturns to  a normal  level  [9]. -D-glucan  is a  cell
all antigen  that  is  common  to  most  fungi.  Studies
ndicate  good  sensitivity  of  -D-glucan  for  invasive
ungal infections  including  aspergillosis.  However,
peciﬁcity  is  relatively  low  for  aspergillosis  and
alse positive  tests  have  occurred  in  bacterial  infec-
ions and  patients  on  haemodialysis  [25].  There
re currently  no  data  to  suggest  its  use  to  moni-
or response  to  antifungal  therapy.  Aspergillus  DNA
etection  by  real-time  PCR  is  promising  in  the  early
iagnosis  of  IA;  however,  it  is  not  widely  used  in
linical practice.  Imaging  through  high-resolution
T scan  of  the  chest  has  been  shown  to  aid  in  the
arly detection  of  early  lung  lesions  that  suggest
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spergillosis  [26—29].  The  expert  panel  recom-
ends that  it  should  be  considered  early  in  patients
t risk  of  IA.
onsensus recommendations for
reatment of disease-speciﬁc
spergillus infections
he  following  agents  have  been  approved  by  the
ood and  Drug  Administration  (FDA)  in  the  United
tates of  America  and  the  European  Medicines
gency for  the  treatment  of  IA:  Amphotericin  B
eoxycholate  (AMB-D)  and  the  lipid  formulations
AMB lipid  complex  [ABLC],  liposomal  ampho-
ericin B  [L-AMB]  and  AMB  colloidal  dispersion
ABCD]), itraconazole,  voriconazole,  posaconazole
nd caspofungin.  Treatment  of  IA  should  be  aggres-
ive and  started  early  upon  suspecting  the  disease
s delayed  therapy  is  associated  with  worse  out-
ome (A).  Voriconazole  is  the  ﬁrst-line  therapy
n most  conditions,  followed  by  other  licensed
ntifungal therapy  as  published  data  have  shown
etter  efﬁcacy  compared  with  AMB-D.  A  large
rospective, randomised  trial  for  the  treatment  of
nvasive pulmonary  aspergillosis  demonstrated  that
oriconazole  was  superior  to  AMB-D  [30]. L-AMB  was
tudied in  lower  and  higher  doses  in  a  prospective
andomised trial  and  showed  equal  efﬁcacy  of  both
oses in  IA.  Other  agents  such  as  the  echinocan-
ins, ABLC  and  other  triazoles  were  studied  in
on-randomised  prospective  salvage  therapy  trials.
 different  class  of  antifungals  should  be  considered
or therapy  in  patients  on  mould-active  prophylac-
ic antifungal  treatment.  In  the  Middle  East  region,
reatment  of  IA  is  often  determined  by  economic
ressures. As  a  result,  many  public-sector  hospi-
als may  use  AMB-D  or  itraconazole  due  to  limited
esources  and  limited  access  to  more  costly  antifun-
als.  Periodic  testing  for  liver  and  renal  functions  is
ecommended  to  monitor  for  antifungal  toxicity.
nvasive pulmonary aspergillosis
oriconazole  (A)  is strongly  recommended  as  pri-
ary therapy.  The  superiority  of  voriconazole  over
MB-D was  demonstrated  in  the  largest  prospec-
ive, randomised  trial  for  the  treatment  of  invasive
ulmonary  aspergillosis  [30].  Its  efﬁcacy  in  paedi-
tric and  adult  patients  refractory  to  or  intolerant
f conventional  antifungal  therapy  was  further
emonstrated in  other  trials  [31—33].  Lipid  formu-
ations  of  amphotericin  B  (LFAB)  (B),  caspofungin
B), micafungin  (B),  posaconazole  (B),  itracona-
ole (B)  and  AMB-D  can  be  used  as  an  alternative
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n  case  of  failure,  intolerance  or  unavailability  of
oriconazole.  L-AMB,  ABLC,  caspofungin  or  mica-
ungin and  AMB-D  should  be  used  initially  in  patients
n voriconazole  prophylaxis.
Evaluation  of  clinical  signs  and  symptoms  and
eriodic  radiographic  imaging  are  key  elements
f therapeutic  monitoring  of  invasive  pulmonary
spergillosis. Response  to  therapy  can  be  monitored
sing  serial  serum  Aspergillus  galactomannan  and
T scan  of  the  chest.
Despite  medical  therapy  with  voriconazole,  IA  of
he heart,  great  vessels,  pleural  space  and  bone
sually  warrants  surgical  intervention.  Surgical
esection of  pulmonary  lesions  due  to  Aspergillus
pp. can  be  useful  for  deﬁnitive  diagnosis  and
otential  localised  eradication  (B).  In  the  case
f solitary  lung  lesions,  resection  of  the  lesion
r lobectomy  may  be  warranted,  especially  in
atients  with  haemoptysis  [27,34,35].  Surgical
herapy should  also  be  considered  for  patients  with
hest wall  invasion  or  with  lesions  located  close
o the  pericardium  or  the  great  vessels.  This  can
revent  erosion  of  pulmonary  lesions  into  the  great
essels and  pericardial  space  as  well  as  relieve  pain
nd prevent  pleurocutaneous  ﬁstula.
In patients  undergoing  chronic  immunosuppress-
ve therapies,  the  panel  agreed  that  antifungal
herapy should  be  continued  throughout  the  dura-
ion of  immunosuppression  as  this  seems  to  be
ssociated  with  a more  favourable  outcome  (B).
his should  be  guided  by  radiologic  resolution
f Aspergillus  lesions.  Withdrawing  or  reducing
he dose  of  corticosteroids  is  advisable  in  IA  (C).
ecurrent  infection  can  be  prevented  by  resuming
ntifungal therapy  in patients  successfully  treated
or IA  in  the  past  who  will  require  future  immu-
osuppressive therapy,  especially  when  leading  to
eutropenia  (B)  [36,37].
racheobronchial aspergillosis
racheobronchial  involvement  is  an  uncommon
orm of  invasive  pulmonary  aspergillosis.  Early
reatment  may  prevent  anastomotic  disruption  and
oss of  the  lung  graft.  The  panel  recommended
oriconazole  (B)  as  primary  therapy  and  LFAB  (C)
s alternative  therapy.  Little  data  are  available
n the  use  of  echinocandins  or  posaconazole  (C).
erosolised  LFAB  may  be  considered  to  deliver  high
oncentrations  of  polyene  therapy  to  the  infected
ite (C).nvasive sinus aspergillosis
oriconazole  (C)  can  be  used  as  a  ﬁrst-line  treat-
ent when  the  infection  is  known  to  be  due  to
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Aspergillus  [38].  Posaconazole  and  itraconazole
(C) are  a  suitable  alternative  treatment.  However,
given that  voriconazole  and  itraconazole  lack  clin-
ical activity  against  sinonasal  zygomycosis,  LFAB
or AMB-D  (B)  can  be  started  when  the  diagnosis
of aspergillosis  cannot  be  conﬁrmed  and  sinonasal
zygomycosis cannot  be  ruled  out.  Surgical  referral
early  on  is  critical  in  most  cases  of invasive  fungal
sinusitis  (B).  The  resection  of  the  infected  tissues
and/or  the  extent  of  debridement  will  vary  and  is
based on  the  extent  of  disease  and  the  patient’s
condition.
Chronic necrotising pulmonary aspergillosis
(CNPA)
Based  on  the  limited  number  of  studies  for  the
treatment  of  CNPA  [39—43], the  expert  panel
recommends the  use  of  orally  administered  itra-
conazole  (C),  posaconazole  (C)  or  voriconazole  (C)
as a  ﬁrst-line  treatment.  L-AMB  (C),  ABLC  (C),
caspofungin  (C)  and  micafungin  (C)  can  be  used
as alternatives.  The  duration  of  therapy  is  vari-
able  and  depends  on  the  clinical  and  radiological
response. In  most  instances  therapy  is  required  for
3—6 months,  which  warrants  the  use  of  oral  anti-
fungal therapy.
Aspergillosis of the CNS
CNS  aspergillosis  is  the  most  devastating  infec-
tious manifestation  caused  by  Aspergillus  spp.
The evidence  regarding  effective  systemic  ther-
apy for  aspergillosis  of  the  CNS  supports  the  use
of voriconazole  (B)  as  the  ﬁrst-line  treatment
[44].  Alternative  therapies  for  those  refractory  to
voriconazole  include  posaconazole  (C),  LFAB  (C)  and
itraconazole  (C).  Surgical  resection  may  be  needed
for diagnosis  and  could  aid  in  response  to  antifun-
gal therapy  [45,46]. Resection  of  the  infected  tissue
and the  extent  of  debridement  may  vary  based  on
location,  neurological  sequelae,  accessibility  and
surgical judgement.
Aspergillus infections of the heart
(endocarditis, pericarditis, myocarditis)
Cardiac  aspergillosis  carries  a  poor  prognosis.
Timely and  aggressive  treatment  is  paramount
for a  successful  outcome.  The  expert  panel  rec-
ommended  LFAB  (B)  and  AMB-D  (B)  as  ﬁrst-line
treatment. Voriconazole  (C),  caspofungin  (C),  mica-
fungin (C),  posaconazole  (C)  and  itraconazole  (C)
can be  used  as  alternatives.
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Combined  antifungal  therapy  and  surgical
esection of  the  infected  valve  or  mural  lesion
an lead  to  successful  management  of  Aspergillus
ndocarditis. Surgical  debridement  is imperative
or the  survival  of  almost  all  cases  of  Aspergillus
ndocarditis and  most  patients  are  treated  with
mphotericin  [47—49]. Systemic  antifungal  therapy
s the  preferred  treatment  approach  for  Aspergillus
yocarditis as  it  usually  occurs  in  cases  of  dissem-
nated disease.  In  pericarditis,  pericardiectomy
educes organism  burden  around  the  heart  and
ay prevent  tamponade.
Antifungal  therapy  for  aspergillosis  of  the  heart
hould  be  continued  for  not  less  than  6  weeks  after
urgical  intervention  (C).  Patients  with  a  history  of
nfected prosthetic  valve  are  at  risk  for  recurrent
nfections. In  such  case,  lifelong  antifungal  therapy
ith an  antifungal  triazole,  such  as  oral  voricona-
ole or  posaconazole  (C),  should  be  considered.
spergillus osteomyelitis and septic
rthritis
spergillus  osteomyelitis  and  arthritis  usually
equire a  combination  of  systemic  antifungal  ther-
py and  surgical  management.  First-line  therapies
re voriconazole  (B),  AMB-D  (B)  and  surgery.  L-
MB (B),  ABLC  (B),  caspofungin  (B),  micafungin
B), posaconazole  (B)  and  itraconazole  (B)  can  be
sed as  alternatives  following  failure  of  voricona-
ole. There  is  a role  for  surgical  debridement
f the  infected  bone  and  surgical  evaluation
etermines  the  extent  of  surgery  [50]. Successful
reatment of  Aspergillus  arthritis  often  results  from
 combination  of  medical  therapy  and  drainage
f the  joint  based  on  the  clinical  presentation
nd requires  6  weeks  or  more  of  antifungal
herapy [51].
spergillus infections of the eye
endophthalmitis and keratitis)
spergillus  endophthalmitis  and  keratitis  are  dev-
stating infections  that  may  result  in  vision  loss  for
hose affected.  AMB-D  (B)  and  voriconazole  (B)  can
e used  as  ﬁrst-line  treatment.  Alternatives  include
-AMB (B),  ABLC  (B),  posaconazole  (C),  itraconazole
C), caspofungin  (C)  and  micafungin  (C).  Treatment
f Aspergillus  endophthalmitis  with  intravenous
MB or  intravitreal  AMB  plus  vitrectomy  may  be
ight saving.  Systemic  or  intravitreal  injection  of
oriconazole  should  be  considered  as  second-line
herapy [52,53]. Ophthalmologic  surgical  inter-
ention  is  warranted  in  cases  with  potential  for
orneal  perforation  or  disease  progression  despite
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flinical  practice  guidelines  for  the  treatment  of  inv
edical  therapy.  Management  of  Aspergillus  ker-
titis requires  emergency  ophthalmologic  inter-
ention  with  ophthalmologic  examination,  topical
ntifungal  therapy,  and  systemic  antifungal  therapy
ith AMB,  voriconazole  or  itraconazole  [9].  Surgical
ntervention,  including  debridement,  lamellar  ker-
tectomy or  a  conjunctival  ﬂap,  is  often  required.  If
he cornea  remains  infected  despite  topical  therapy
nd there  is  a  risk  of  corneal  perforation,  surgi-
al resection  and  corneal  transplantation  might  be
ecessary.
utaneous asergillosis
utaneous  aspergillosis  often  results  from  sec-
ndary  haematogenous  dissemination  in  immuno-
ompromised  patients  [54,55]. Systemic  voricona-
ole (A)  is  recommended  as  ﬁrst-line  therapy.
-AMB (B),  posaconazole  (B),  itraconazole  (B)  and
chinocanins  (B)  are  acceptable  alternatives.  Sur-
ical intervention  may  be  considered,  particularly
n primary  cutaneous  infection.
spergillus peritonitis
atients  on  peritoneal  dialysis  are  at  risk  of
spergillus peritonitis  [56]. Dialysis  catheter
emoval and  medical  management  with  intravenous
nd intraperitoneal  AMB-D  was  recommended  by
he panel  as  ﬁrst-line  therapy.  Alternative  treat-
ents  are  itraconazole  (C),  voriconazole  (C),
osaconazole  (C)  and  LFAB  (C).
Disease-speciﬁc  guidelines  and  dosing  recom-
endations for  invasive  aspergillosis  are  listed  in
ables  3 and  4.
mpirical antifungal therapy
eutropenic  patients  with  persistent  fever  despite
ntibacterial  therapy  are  at  signiﬁcant  risk  of  devel-
ping an  invasive  fungal  infection.  The  importance
f early  initiation  of  AMB-D  in  these  patients  for  the
reatment  of  IA  was  highlighted  in  previous  reports
57,58].  However,  in  later  trials,  L-AMB,  caspofun-
in and  itraconazole  were  found  to  be  as  effective
s, but  less  nephrotoxic  than,  AMB-D  [59—61]. The
xpert panel  agreed  that  ﬁrst-line  therapies  of
robable  aspergillosis  in  patients  who  are  neu-
ropenic  with  prolonged  fever  include  L-AMB  (A),
aspofungin  (A),  voriconazole  (A)  and  itraconazole
A). AMB-D  (A)  is recommended  as  an  alternative
herapy.
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rophylaxis
rophylactic  treatment  against  IA  remains  a chal-
enge as  appropriate  patient  selection  is  difﬁcult.
ccording  to  the  IDSA  2008  guidelines,  the  patients
ost likely  to  beneﬁt  from  prophylaxis  therapy
re those  with  prolonged  neutropenia  and  severe
VHD,  lung  transplant  recipients,  patients  receiv-
ng long-term  high-dose  corticosteroid  therapy,
ome liver  transplant  recipients  and  those  with
ertain  inherited  immunodeﬁciency  disorders.  The
ecommended  ﬁrst-line  treatment  in  patients  at
igh risk  for  IA  (i.e.  haematopoietic  stem  cell
ransplantation recipients  and  patients  with  acute
yelogenous  leukaemia  or  myelodysplastic  syn-
rome)  is  posaconazole  (A).  Voriconazole  can  be
n alternative  therapy  in  recipients  of  allogeneic
one marrow  transplantation  (A).  Micafungin  can  be
sed in  the  pre-engraftment  phase  following  HSCT
A). For  patients  refractory  or  intolerant  to  ﬁrst-
ine therapy,  itraconazole  (B)  and  echinocandins  are
ossible alternatives  (C).  The  use  of  high-efﬁciency
articulate air  ﬁltration  (HEPA)  ﬁlters  for rooms
r wards  of  neutropenic  patients  is  highly  recom-
ended  [62,63].
ombination therapy
he  expert  panel  agreed  that  there  are  insufﬁ-
ient data  to  recommend  combination  therapy  for
he treatment  of  invasive  Aspergillus  infections.
urrent data  are  mostly  from  retrospective  stud-
es and  inconclusive.  A  recent  large  prospective
andomised trial  on  the  combination  of  anidulafun-
in and  voriconazole  versus  voriconazole  alone  for
herapy  of  IA  was  presented  in  abstract  form.  The
tudy indicates  a trend  towards  a better  response
ith the  combination  regimen  but  did  not  reach  sta-
istical signiﬁcance.  This  study  cannot  be  evaluated
ntil  full  publication  [64].
uration of treatment
uration  of  antifungal  therapy  for  invasive  pul-
onary  aspergillosis  is  not  well  deﬁned.  After
eview of  the  evidence  the  expert  panel  agreed  that
o ﬁxed  duration  of  therapy  can  be  recommended
or invasive  Aspergillus  infections.  The  treatment
uration will  depend  on  the  individual  patient,  the
ite of  infection,  the  extent  of  the  disease  and  the
mmunosuppression  status.  Antifungal  therapy  may
e continued  for  several  months  (a  minimum  of
28  H.M.  Al-Abdely  et  al.
Table  3  Disease-speciﬁc  guidelines.
Condition  Primary  therapy  Alternative  therapy
Invasive  pulmonary  aspergillosis  Voriconazole  (A)  LFAB  (B)
Caspofungin  (B)
Micafungin  (B)
Posaconazole  (B)
Itraconazole  (B)
Anidulafungin  (C)
Tracheobronchial  aspergillosis  Voriconazole  (B)  LFAB  (C)
Invasive  sinus  aspergillosisa Voriconazole  (C)  Posaconazole  (C)
LFAB  (C)
CNPA  (subacute  invasive  pulmonary
aspergillosis)
Voriconazole  (C)
Posaconazole  (C)
Itraconazole  (C)
LFAB  (C)
Itraconazole  (C)
Echinocandins  (C)
Aspergillosis  of  the  CNS  Voriconazole  (B)  L-AMB  (C)
Posaconazole  (C)
ABLC  (C)
Itraconazole  (C)
Aspergillus  infections  of  the  heart
(endocarditis,  pericarditis  and
myocarditis)
LFAB  (C)
AMB-D  (C)
Voriconazole  (C)
Posaconazole  (C)
Itraconazole  (C)
Echinocandins  (C)
Aspergillus  osteomyelitis  and  septic
arthritis
Voriconazole  (B)
AMB-D  (B)
Similar  to  invasive  pulmonary
aspergillosis
Aspergillus  infections  of  the  eye
(endophthalmitis  and  keratitis)
AMB-D  (C)
Voriconazole  (C)
Similar  to  invasive  pulmonary
aspergillosis;  limited  data  with
echinocandins
Cutaneous  aspergillosis  Voriconazole  (A)  Posaconazole  (B)
Itraconazole  (B)
LFAB  (B)
Echinocanins  (B)
Aspergillus  peritonitis  AMB-D  (C)  Itraconazole  (C)
Voriconazole  (C)
Posaconazole  (C)
LFAB  (C)
AMB-D, amphotericin B deoxycholate; CNPA, chronic necrotising pulmonary aspergillosis; CNS, central nervous system; L-AMB,
liposomal amphotericin B; LFAB, lipid formulations of amphotericin B.
a If Zygomycosis is suspected LFAB is the preferred initial therapy.
Table  4  Dosing  recommendations  for  invasive  aspergillosis.
Agent  Dose
Micafungin  100  mg  daily
Anidulafungin  200  mg,  then  100  mg  daily
Caspofungin  Loading  dose  (LD)  70  mg,  then  50  mg  daily
Voriconazole  6  mg/kg  every  12  h  for  2  doses,  then  4  mg/kg  every  12  h
Posaconazole  200  mg  three  times  a  day.  Alternatively,  patients  who  can
tolerate  food  or  a  nutritional  supplement  may  take  400  mg
(10  ml)  twice  a  day  during  or  immediately  following  a  meal  or
nutritional  supplement
Itraconazole  (oral)  200  mg  twice  daily  in  case  of  invasive  or  disseminated  disease.
Avoid  stomach  acid  suppressants  with  capsule  formulation.
LFAMB  3—5  mg/kg  daily
AMB-D  0.5—1.0  mg/kg  daily
AMB-D, amphotericin B deoxycholate; LFAM, lipid formulations of amphotericin B.
The expert panel recommends using the doses within the prescribing information unless otherwise stated.
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Rlinical  practice  guidelines  for  the  treatment  of  inv
—12  weeks)  when  used  alongside  regular  monitor-
ng (B).
imitations and future direction
hese  guidelines  summarise  the  consensus  agree-
ent of  an  expert  panel  for  the  treatment  of
nvasive Aspergillus  infections  in  the  Middle  East
nd are  based  on  a  review  and  analysis  of  the
ost recent  international  guidelines  and  published
iterature.  The  development  of  these  guidelines
as needed  to  guide  clinicians  in  providing  the
est treatment  while  considering  regional  limita-
ions in  the  areas  of  epidemiology,  diagnosis  and
herapeutic  options.  The  limited  epidemiological
ata available  from  the  Middle  East  highlight  the
eed for  appropriate  reporting  and  documenting  of
he diagnosis  of  invasive  Aspergillus  infections.  The
iagnosis  of  infection  in  the  region  relies  primar-
ly on  conventional  techniques,  such  as  microscopy
nd culture.  The  availability  of  tests  such  as  galac-
omannan,  -D-glucan  test  and  DNA  detection  of
nvasive Aspergillus  infections  is  limited  to  a few
entres.  The  expert  panel  agreed  that  every  effort
hould  be  made  to  diagnose  infections  to  a  species
evel and  a  local  reference  laboratory  should  be
tilised  if  resources  are  not  available  in  a  local  hos-
ital.
Members  of  the  working  group  acknowledged
hat these  guidelines  should  be  followed  as  closely
s possible  and  used  alongside  clinical  judgement.
xpert advice  should  be  sought  from  local  ref-
rence centres  when  required  to  fully  diagnose
nd optimally  treat  invasive  Aspergillus  infection.
hile these  recommendations  will  actively  change
n response  to  emerging  data  from  the  region,  the
xpert panel  hopes  that  their  implementation  will
mprove  mortality  rates  from  IA  in  the  Middle  East.
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